ストックスクリーナーアプリを入手
79.49
3.52%
-2.90
前日終値:
$82.39
開ける：
$83.16
24時間の取引高:
319.93K
Relative Volume:
0.73
時価総額：
$5.65B
収益：
-
当期純損益:
$-224.29M
株価収益率:
-22.91
EPS:
-3.47
ネットキャッシュフロー:
$-153.27M
1週間 パフォーマンス:
+2.00%
1か月 パフォーマンス:
+1.55%
6か月 パフォーマンス:
-3.83%
1年 パフォーマンス:
-3.68%
1日の値動き範囲:
$79.34
$83.63
1週間の範囲:
$77.90
$83.63
52週間の値動き範囲:
$61.80
$113.51
Nuvalent Inc Stock (NUVL) Company Profile
NUVL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
79.49 | 5.65B | 0 | -224.29M | -153.27M | -3.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-10-24 | 開始されました | UBS | Neutral |
| 2024-08-29 | 開始されました | Barclays | Overweight |
| 2024-04-17 | 開始されました | Jefferies | Buy |
| 2024-04-01 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | 再開されました | Guggenheim | Buy |
| 2024-02-23 | 開始されました | Robert W. Baird | Outperform |
| 2023-09-27 | 開始されました | Stifel | Buy |
| 2023-08-08 | 開始されました | SVB Securities | Market Perform |
| 2023-07-24 | 開始されました | Guggenheim | Buy |
| 2023-01-18 | 開始されました | Wedbush | Outperform |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
すべてを表示
Nuvalent Inc (NUVL) 最新ニュース
Nuvalent CEO sells stock worth over $2.1 million - Investing.com India
Nuvalent CEO sells stock worth over $2.1 million By Investing.com - Investing.com UK
(NUVL) Proactive Strategies - Stock Traders Daily
Nuvalent (NUVL) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Nuvalent, Inc. (NASDAQ:NUVL) Receives $112.36 Consensus Target Price from Analysts - MarketBeat
Q1 Earnings Estimate for Nuvalent Issued By Leerink Partnrs - MarketBeat
abrdn plc Buys 9,241 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
Nuvalent, Inc. (NASDAQ:NUVL) Receives $112.36 Consensus PT from Brokerages - Defense World
10 Mid-Cap Stocks Insiders Are Selling Recently - Insider Monkey
Why Insiders Are Selling Nuvalent, Inc. (NUVL) Recently - Insider Monkey
What is Leerink Partnrs' Forecast for Nuvalent Q2 Earnings? - MarketBeat
KBC Group NV Boosts Stock Holdings in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
What is Leerink Partnrs’ Forecast for Nuvalent Q2 Earnings? - Defense World
Long Term Trading Analysis for (NUVL) - Stock Traders Daily
Nuvalent (NASDAQ:NUVL) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
The Potential Rise in the Price of Nuvalent Inc (NUVL) following insiders activity - Knox Daily
Nuvalent Inc (NUVL) is looking forward to a strong quarter - SETE News
Top 10 Takeover Targets of 2025 - Genetic Engineering & Biotechnology News
Nuvalent, Inc. (NASDAQ:NUVL) Director Sells $165,580.00 in Stock - MarketBeat
Nuvalent, Inc. (NASDAQ:NUVL) Stock Holdings Raised by SG Americas Securities LLC - MarketBeat
Vanguard Group Inc's Strategic Acquisition of Nuvalent Inc Shares - GuruFocus.com
Nuvalent director Matthew Shair sells shares worth $165,575 - MSN
Nuvalent director Matthew Shair sells shares worth $165,575 By Investing.com - Investing.com Canada
How To Trade (NUVL) - news.stocktradersdaily.com
Bullish Two Hundred Day Moving Average CrossNUVL - Nasdaq
Nuvalent: A First Look (NASDAQ:NUVL) - Seeking Alpha
Is Nuvalent, Inc. (NUVL) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Nuvalent’s (NUVL) “Buy” Rating Reiterated at HC Wainwright - Defense World
Nuvalent stock reiterates buy rating on FDA approval potential - MSN
Nuvalent CEO Porter James Richard sells shares worth $2.05m - MSN
JPMorgan Chase & Co. Has $3.55 Million Stake in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) CEO James Richard Porter Sells 27,000 Shares - MarketBeat
Nuvalent CEO Porter James Richard sells shares worth $2.05m By Investing.com - Investing.com Canada
HC Wainwright Reiterates Buy Rating for Nuvalent (NASDAQ:NUVL) - MarketBeat
Nuvalent stock reiterates buy rating on FDA approval potential By Investing.com - Investing.com Canada
Nuvalent's SWOT analysis: biotech stock shows promise amid clinical progress - Investing.com Canada
(NUVL) Trading Report - Stock Traders Daily
Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Nuvalent Announces Corporate Updates and Anticipated Milestones for 2025 - Defense World
Nuvalent's SWOT analysis: biotech's lung cancer drug stock shows promise amid risks - Investing.com Australia
Nuvalent's SWOT analysis: biotech's lung cancer drug stock shows promise amid risks By Investing.com - Investing.com South Africa
Nuvalent’s (NUVL) Outperform Rating Reaffirmed at Wedbush - Defense World
Nuvalent (NASDAQ:NUVL) Given "Outperform" Rating at Wedbush - MarketBeat
Nuvalent Inc (NUVL) 財務データ
収益
当期純利益
現金流量
EPS
Nuvalent Inc (NUVL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Porter James Richard | President and CEO |
Feb 18 '25 |
Sale |
78.46 |
27,000 |
2,118,336 |
249,062 |
| Pelish Henry E. | Chief Scientific Officer |
Jan 31 '25 |
Option Exercise |
0.87 |
3,120 |
2,714 |
63,101 |
| Shair Matthew | Director |
Jan 27 '25 |
Sale |
82.79 |
2,000 |
165,576 |
218,522 |
| Porter James Richard | President and CEO |
Jan 15 '25 |
Option Exercise |
27.85 |
27,000 |
751,950 |
276,062 |
| Porter James Richard | President and CEO |
Jan 15 '25 |
Sale |
75.99 |
27,000 |
2,051,777 |
249,062 |
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):